Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium

Table 2 Association of CT-proET-1 and MR-proADM with incident type 2 diabetes

Adjustment	Hazard ratio [95% CI]
Adjustment	N cases/person-years = 862/149,937
CT-proET-1
Model 1	1.30 [1.21; 1.39], P < 0.001
Model 2	1.10 [1.03; 1.18], P = 0.008
Model 2 + eGFR	1.10 [1.03; 1.19], P = 0.007
Model 2 + insulin^a	1.10 [1.02; 1.18], P = 0.012
Model 2 + hsCRP	1.08 [1.01; 1.16], P = 0.026
Model 2 + leptin	1.09 [1.02; 1.17], P = 0.018
Model 2 + eGFR, insulin, hsCRP, leptin	1.09 [1.01; 1.17], P = 0.021
MR-proADM
Model 1	1.57 [1.45; 1.69], P < 0.001
Model 2	1.11 [1.02; 1.21], P = 0.016
Model 2 + eGFR	1.12 [1.02; 1.22], P = 0.013
Model 2 + insulin^a	1.09 [1.00; 1.18], P = 0.061
Model 2 + hsCRP	1.08 [0.99; 1.18], P = 0.073
Model 2 + leptin	1.08 [0.99; 1.18], P = 0.089
Model 2 + eGFR, insulin, hsCRP, leptin	1.07 [0.98; 1.17], P = 0.153

The associations were computed using Cox regression models per 1-SD increment of log (MR-proADM) and CT-proET-1. The distributions of MR-proADM, insulin, hsCRP, and leptin were right-skewed and thus, were log-transformed to approximate normality
CI confidence interval, CT-proET-1 C-terminal-proendothelin-1, eGFR estimated glomerular filtration rate, hsCRP high-sensitivity C-reactive protein, MR-proADM mid-regional-proadrenomedullin
Model 1: adjusted for age (continuous, in years), sex (man/woman) and cohort (as a stratum variable);
Model 2: Model 1 + actual hypertension (yes/no), total and high-density lipoprotein cholesterol (continuous, in mmol/l), current smoking status (yes/no) and body mass index (continuous, in kg/m²)
^a97% of study participants were fasting at least 4 h and the exclusion of those who were not fasting or whose fasting status was unknown did not change the results

ISSN: 1475-2840